Project: Secretoneurin (SN): a breakthrough blood biomarker for heart disease and sudden Cardiac Arrest risk

Acronym SeNCA (Reference Number: 11989)
Duration 31/03/2018
Project Topic Secretoneurin (SN) is a novel biomarker that improves risk prediction in cardiovascular disease by reflecting additional pathophysiology to established risk indices. SeNCA will bring this innovation towards market entry by developing and validating a SN ELISA and by documenting that SN identifies patients with increased risk of ventricular arrhythmias. The assay will be launched as a Research use Only (RuO) version immediately after SeNCA and as CE-marked version 12 months post-project.
Network Eurostars 2
Call Eurostars Cut-Off 8

Project partner

Number Name Role Country
1 CardiNor AS (CNOR) Coordinator Norway
3 Bioventix PLC (BIOV) Partner United Kingdom
4 Kaivogen OY (KAIV) Partner Finland